Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Early Aspirin After Clot-Dissolving Treatment for Acute Ischemic Stroke

Tests early oral aspirin in adults with stroke treated with intravenous thrombolysis.

Plain-language title generated from the registry record
Registry title: Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)

Key facts

Where
Anshan, Anyang, Baoji, Beijing, Bengbu, Bozhou, Cangzhou, Changde, Changsha, Chengdu, Chenzhou, Dalian, Dandong, Datong, Dezhou, Dongying, Fushun, Fuxin, Fuzhou, Guangzhou, Guankou, Guigang, Haerbin, Haidian, Haikou, Hainan, Handan, Hebi, Heyuan, Huaibei, Jiamusi, Jiangzuo, Jiaxing, Jinan, Jingdezhen, Jingmen, Jining, Kaifeng, Kaili, Lianyungang, Liaocheng, Linfen, Loudi, Luoyang, Mudanjiang, Nanchang, Nanyang, Neimeng, Pinggu, Puyang, Qingdao, Qiqihar, Rizhao, Sanmenxia, Shangqiu, Shangqucun, Shanyang, Shenzhen, Shihezi, Suzhou, Taian, Tangshan, Tianjin, Tongliao, Tongzhou, Ulanqab, Weifang, Weihai, Wenshan, Wuzhou, Xiamen, Xiangtan, Xiangxiang, Xiangyang, Xingan, Xingtai, Xinyang, Xuzhou, Ya'an, Yongzhou, Zhalantun, Zhangzhou, Zhoukou, Zhumadian, Zhuzhou, and Zibo, ChinaSee the 119 sites
Phase
Phase 3

Where in China

  • Anshan Changda HospitalAnshan, ChinaNot yet recruiting
  • Hua county People's HospitalAnyang, ChinaTaking people
  • Baoji Fengxiang district hospitalBaoji, ChinaNot yet recruiting
  • Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaTaking people
  • Huaiyuan county traditional Chinese medicine hospitalBengbu, ChinaTaking people
  • The Third The People's Hospital Of BengbuBengbu, ChinaTaking people
  • Bozhou People's HospitalBozhou, ChinaNot yet recruiting
  • Botou traditional Chinese medicine hospitalCangzhou, ChinaTaking people
  • Cangzhou Central HospitalCangzhou, ChinaTaking people
  • Cangzhou combination of Chinese traditional and western medicine hospitalCangzhou, ChinaTaking people
  • Hejian city People's HospitalCangzhou, ChinaTaking people
  • Xian county People's HospitalCangzhou, ChinaTaking people
  • Li county people's hospitalChangde, ChinaNot yet recruiting
  • The First People's Hospital of Changde CityChangde, ChinaTaking people
  • XiangYa Hospital CentralSouth UniversityChangsha, ChinaNot yet recruiting
  • Chengdu Second People's HospitalChengdu, ChinaTaking people
  • Chenzhou First People's HospitalChenzhou, ChinaTaking people
  • Lvshunkou district traditional Chinese medicine hospitalDalian, ChinaTaking people
  • Donggang city Central HospitalDandong, ChinaTaking people
  • Datong Third People's HospitalDatong, ChinaTaking people
  • Ningjin County People's HospitalDezhou, ChinaTaking people
  • Dongying People's HospitalDongying, ChinaTaking people
  • Shengli Oilfield Central HospitalDongying, ChinaTaking people
  • Fushun Mining Bureau General HospitalFushun, ChinaTaking people
  • Fuxin People's HospitalFuxin, ChinaTaking people
  • Fujian university affiliated provincial hospitalFuzhou, ChinaTaking people
  • Brain Hospital Affiliated to Guangzhou Medical UniversityGuangzhou, ChinaTaking people
  • Liuyang Jili HospitalGuankou, ChinaTaking people
  • Guigang people's hospitalvGuigang, ChinaTaking people
  • Harbin 242 hospitalHaerbin, ChinaTaking people
  • Aerospace central hospitalHaidian, ChinaTaking people
  • The Second Affiliated Hospital of Hainan Medical UniversityHaikou, ChinaTaking people
  • The Third People's Hospital of Hubei ProvinceHainan, ChinaTaking people
  • Ci county people's hospitalHandan, ChinaTaking people
  • Handan Central HospitalHandan, ChinaTaking people
  • Handan First HospitalHandan, ChinaTaking people
  • Handan Yongnian District First HospitalHandan, ChinaTaking people
  • Jun county people's hospitalHebi, ChinaTaking people
  • Heyuan People's HospitalHeyuan, ChinaTaking people
  • People's Hospital of Longchuan CountyHeyuan, ChinaNot yet recruiting
  • Huaibei People's HospitalHuaibei, ChinaTaking people
  • Jiamusi University Hongda HospitalJiamusi, ChinaTaking people
  • Jiaozuo Second People's HospitalJiangzuo, ChinaTaking people
  • Haiyan People's HospitalJiaxing, ChinaTaking people
  • Jinan Third People's HospitalJinan, ChinaTaking people
  • Shandong province qianfoshan hospitalJinan, ChinaTaking people
  • Jingdezhen No.1 People's HospitalJingdezhen, ChinaTaking people
  • Jingmen People's HospitalJingmen, ChinaNot yet recruiting
  • Jiaxiang county people's hospitalJining, ChinaTaking people
  • Kaifeng Central HospitalKaifeng, ChinaTaking people
  • The Second Affiliated Hospital of Guizhou Medical UniversityKaili, ChinaTaking people
  • Donghai County People's HospitalLianyungang, ChinaTaking people
  • Gaotang county people's hospitalLiaocheng, ChinaTaking people
  • Liaocheng People's HospitalLiaocheng, ChinaTaking people
  • The Third People Hospital in LiaochengLiaocheng, ChinaTaking people
  • Linfen People's HospitalLinfen, ChinaNot yet recruiting
  • Lengshuijiang People's HospitalLoudi, ChinaTaking people
  • First People's Hospital of LuoyangLuoyang, ChinaTaking people
  • Luoyang Yanshi People's HospitalLuoyang, ChinaTaking people
  • Luoyang Yiluo HospitalLuoyang, ChinaTaking people
  • Mengjin county people's hospitalLuoyang, ChinaTaking people
  • Mudanjiang First People's HospitalMudanjiang, ChinaTaking people
  • The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
  • Nanyang Central HospitalNanyang, ChinaTaking people
  • Nanyang Nanshi HospitalNanyang, ChinaTaking people
  • Togtoh county hospitalNeimeng, ChinaTaking people
  • Beijing Pinggu District HospitalPinggu, ChinaTaking people
  • Nanle county people's hospitalPuyang, ChinaTaking people
  • Pingdu city traditional Chinese medicine hospitalQingdao, ChinaTaking people
  • The first hospital of QiqiharQiqihar, ChinaTaking people
  • Juxian county people's hospitalRizhao, ChinaTaking people
  • Rizhao traditional Chinese medicine hospitalRizhao, ChinaTaking people
  • Huanghe Sanmenxia HospitalSanmenxia, ChinaTaking people
  • Shangqiu First People's HospitalShangqiu, ChinaTaking people
  • Shangqiu Third People's HospitalShangqiu, ChinaTaking people
  • Sui County People's HospitalShangqiu, ChinaTaking people
  • Sui county traditional Chinese medicine hospitalShangqiu, ChinaTaking people
  • Ningling county people's hospitalShangqucun, ChinaTaking people
  • Shaodong county people's hospitalShanyang, ChinaNot yet recruiting
  • Shenzhen Second People's HospitalShenzhen, ChinaTaking people
  • Shihezi City People's HospitalShihezi, ChinaTaking people
  • Suzhou Municipal HospitalSuzhou, ChinaTaking people
  • The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
  • The Fourth Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
  • Shandong health group feicheng hospitalTaian, ChinaTaking people
  • Yutian County HospitalTangshan, ChinaTaking people
  • Tianjin Xiqing HospitalTianjin, ChinaTaking people
  • Affiliated Hospital of Inner Mongolia University for the NationalitiesTongliao, ChinaTaking people
  • Kezuo Zhongqi People's HospitalTongliao, ChinaTaking people
  • Beijing Luhe Hospital affiliated to Capital Medical UniversityTongzhou, ChinaTaking people
  • Ulanqab Central HospitalUlanqab, ChinaTaking people
  • Weifang People's HospitalWeifang, ChinaTaking people
  • Weihai Central HospitalWeihai, ChinaTaking people
  • Weihai Municipal HospitalWeihai, ChinaTaking people
  • Wenshan Zhou people's hospitalWenshan, ChinaTaking people
  • Wuzhou Red Cross HospitalWuzhou, ChinaTaking people
  • The First Affiliated hospital of Xiamen UniversityXiamen, ChinaTaking people
  • Xiamen Xinglin hospitalXiamen, ChinaTaking people
  • Xiangtan Central HospitalXiangtan, ChinaTaking people
  • Xiangxiang people's hospitalXiangxiang, ChinaNot yet recruiting
  • Xiangyang Central HospitalXiangyang, ChinaTaking people
  • Tuquan county people's hospitalXingan, ChinaNot yet recruiting
  • Qinghe County People's HospitalXingtai, ChinaTaking people
  • Xingtai Ninth HospitalXingtai, ChinaTaking people
  • Xixian county people's hospitalXinyang, ChinaNot yet recruiting
  • Affiliated Hospital of Xuzhou Medical UniversityXuzhou, ChinaTaking people
  • Fengxian county people's hospitalXuzhou, ChinaTaking people
  • Jiawang district People's HospitalXuzhou, ChinaNot yet recruiting
  • Xuzhou Xin health hospitalXuzhou, ChinaTaking people
  • Ya 'an People's HospitalYa'an, ChinaTaking people
  • Ningyuan county People's HospitalYongzhou, ChinaTaking people
  • Zha Lan Tun Shi Zhong Meng Yi YuanZhalantun, ChinaTaking people
  • Zhangzhou Hospital of Fujian ProvinceZhangzhou, ChinaTaking people
  • Luyi county people's hospitalZhoukou, ChinaTaking people
  • Shenqiu County People's HospitalZhoukou, ChinaTaking people
  • Xihua People's HospitalZhoukou, ChinaTaking people
  • Zhumadian Central HospitalZhumadian, ChinaTaking people
  • Zhuzhou Central HospitalZhuzhou, ChinaTaking people
  • Zibo Central hospitalZibo, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Capital Medical University
Trial code
NCT06548971
Record updated
24 September 2026
Original description
Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis.Read full original descriptionShow less

Safety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): A Multicenter, Randomized, Placebo-controlled, Clinical Trial

Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis.

Currently, guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding. The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear.

The study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis, early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage.

Inclusion: Age ≥18 years old; Acute ischemic stroke treated with intravenous thrombolysis with alteplase or tenecteplase within 4.5 hours of onset or time last known well, and can receive the study drug treatment within 3 hours of initiating intravenous thrombolysis; Residual NIHSS score > 5 points assessed 1 hour after initiation of intravenous thrombolysis and prior to randomization; Informed consent obtained from patients or an authorized representative.

Exclusion: Prior history of moderate or severe ischemic stroke events with residual neurological disability; Stroke caused by definite large vessel occlusion (including A1/A2 segments of the anterior cerebral artery, M1/M2 segments of the middle cerebral artery, P1/P2 segments of the posterior cerebral artery, intracranial/extracranial segments of the internal carotid artery, basilar artery, and bilateral vertebral artery occlusion) confirmed by vessel imaging (including computed tomography angiography [CTA] or magnetic resonance angiography [MRA]), or scheduled for endovascular treatment (including mechanical thrombectomy, intra-arterial thrombolysis, and angioplasty); Intracranial hemorrhage confirmed by imaging post-thrombolysis; Definite or suspected cardioembolic stroke; Stroke caused by other determined causes, including nonatherosclerotic vasculopathies (moyamoya disease, artery dissection, arteritis), hypercoagulable states, or hematological disorders; Pre-stroke mRS score > 1; Known contraindications for antiplatelet therapy, such as coagulation disorders, or systemic bleeding; History of aspirin allergy; Anticipated indications for anticoagulant therapy during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid syndrome, hypercoagulable state); Presence of dementia, psychiatric disorders, or other known neurological conditions that complicate follow-up; Other conditions that make the patient unsuitable for participation in the study as determined by the investigator; Use of antiplatelet therapy within one week prior to stroke onset, novel anticoagulant drugs within 48 hours prior to stroke onset, or treatment with warfarin with an international normalized ratio (INR)>1.7; Presence of malignant tumors, chronic hemodialysis, severe renal insufficiency (GFR < 30 mL/min or serum creatinine > 220 μmol/L [2.5 mg/dL]), severe hepatic insufficiency (serum alanine aminotransferase [ALT] >2 times the upper limit of normal, or serum aspartate aminotransferase [AST] >2 times the upper limit of normal), severe heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV); Severe consciousness disturbance with NIHSS item 1a (level of consciousness) ≥ 2 points; Post-thrombolysis imaging indicates an infarct area larger than 1/2 responsible artery supply area; Severe non-cardiovascular complications with an expected survival of less than 6 months; Unavailability for follow-up; Current participation in another therapeutic study with ongoing treatment and follow-up.

ClinicalTrials.gov NCT06548971